<DOC>
	<DOCNO>NCT01451203</DOCNO>
	<brief_summary>The objective study assess efficacy certolizumab pegol ( CZP ) methotrexate ( MTX ) compare MTX-alone patient early-stage rheumatoid arthritis ( RA ) naive MTX poor prognostic factor , use inhibition radiographically confirm joint damage progression one-year period primary endpoint . Following year treatment CZP plus MTX treatment , CZP discontinue , subject monitor one year ( follow-up period ) investigate sustainability efficacy CZP MTX monotherapy exploratory purpose .</brief_summary>
	<brief_title>Efficacy Confirmation Study CDP870 Early Rheumatoid Arthritis</brief_title>
	<detailed_description>This study initiate Otsuka Pharmaceutical Co. , Ltd transfer Astellas 12/04/2012 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subjects RA define ACR/EULAR criterion ( 2010 ) meet follow criterion : 1 . Subjects develop RA within one year onset RA . 2 . Subjects never receive MTX ( MTX naive ) 3 . Subjects whose disease activity moderate high ( DAS28 ( ESR ) ≥ 3.2） 4 . Subjects must satisfy least two three criterion ( AntiCCP antibody positive , Rheumatoid factor positive , Presence Xray erosion） poor prognostic factor . The antiCCP antibody positive essential every patient . Patients diagnosis type inflammatory arthritis . Patients secondary , noninflammatory type arthritis . Patients use MTX , reflunomide , biologics prior start study drug administration . Patients NYHA ( New York Heart Association ) Class III IV congestive heart failure Patients currently , history , tuberculosis . Patients high risk infection ( current infectious disease , chronic infectious disease , history serious infectious disease ) Patients currently , history , malignant tumor Female patient breastfeed pregnant , childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Early RA</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>